Look back at pharma news to Oct 13

15 October 2017

On the politics scene, the biggest topic was US President Donald Trump’s executive order on the Affordable Care Act in his continuing attempt to rid the country of Obamacare. In terms of company news attracting attention, there were disappointing clinical trial results on Eli Lilly’s Verzenio; Good news for AstraZeneca’s Imfinzi and Tagrisso in lung cancer; and Merck & Co finally nailing the coffin on its cholesterol drug candidate anacetrapib.

Trump sabotages the Affordable Care Act with latest executive order

Over a 24-hour period at the end of last week, President Donald Trump took two actions aimed at mortally wounding the Affordable Care Act.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK